ANI Pharmaceuticals (NASDAQ:ANIP) Stock Rating Lowered by Zacks Research

ANI Pharmaceuticals (NASDAQ:ANIP) was downgraded by stock analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a research report issued on Thursday,Zacks.com reports.

ANIP has been the topic of several other research reports. Guggenheim boosted their price target on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the company a “buy” rating in a research report on Friday, January 16th. Wall Street Zen raised shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Five research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, ANI Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $107.33.

ANI Pharmaceuticals Stock Performance

NASDAQ ANIP opened at $78.01 on Thursday. The company’s 50 day moving average is $77.29 and its 200-day moving average is $80.48. ANI Pharmaceuticals has a 12-month low of $56.71 and a 12-month high of $99.50. The company has a quick ratio of 2.52, a current ratio of 3.12 and a debt-to-equity ratio of 1.06. The firm has a market cap of $1.77 billion, a P/E ratio of 19.75 and a beta of 0.46.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.28 by $0.77. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. The company had revenue of $237.46 million for the quarter, compared to analyst estimates of $207.63 million. During the same quarter in the previous year, the firm posted $1.70 earnings per share. The company’s quarterly revenue was up 20.5% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Sell-side analysts predict that ANI Pharmaceuticals will post 7.73 earnings per share for the current year.

Insider Activity at ANI Pharmaceuticals

In related news, insider Christopher Mutz sold 5,323 shares of the business’s stock in a transaction that occurred on Friday, February 20th. The shares were sold at an average price of $78.02, for a total transaction of $415,300.46. Following the completion of the transaction, the insider owned 84,840 shares of the company’s stock, valued at approximately $6,619,216.80. The trade was a 5.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Stephen P. Carey sold 7,312 shares of the business’s stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $75.50, for a total transaction of $552,056.00. Following the transaction, the chief financial officer directly owned 185,543 shares of the company’s stock, valued at approximately $14,008,496.50. This represents a 3.79% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 100,564 shares of company stock valued at $7,800,862 in the last quarter. 8.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On ANI Pharmaceuticals

Several hedge funds have recently bought and sold shares of ANIP. Arrowstreet Capital Limited Partnership purchased a new position in ANI Pharmaceuticals during the third quarter valued at approximately $32,992,000. Balyasny Asset Management L.P. grew its stake in ANI Pharmaceuticals by 2,785.7% in the 3rd quarter. Balyasny Asset Management L.P. now owns 286,149 shares of the specialty pharmaceutical company’s stock worth $26,211,000 after buying an additional 276,233 shares in the last quarter. Divisadero Street Capital Management LP purchased a new position in ANI Pharmaceuticals in the 3rd quarter worth approximately $21,454,000. Rubric Capital Management LP grew its stake in ANI Pharmaceuticals by 354.7% in the 2nd quarter. Rubric Capital Management LP now owns 257,669 shares of the specialty pharmaceutical company’s stock worth $16,813,000 after buying an additional 200,998 shares in the last quarter. Finally, UBS Group AG grew its stake in ANI Pharmaceuticals by 45.8% in the 3rd quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company’s stock worth $54,032,000 after buying an additional 185,172 shares in the last quarter. Hedge funds and other institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.